At Phage Biologics, we exist for one reason: to empower innovators working at the cutting edge of phage science. Our mission is rooted in the belief that phages are not just tools, but transformative platforms capable of reshaping medicine, biotechnology, and materials science. We serve a wide spectrum of clients — from ambitious startups developing the next generation of phage therapeutics, to global pharmaceutical leaders scaling vaccine platforms, to academic pioneers translating breakthroughs into clinical pipelines. Each of these groups faces unique challenges, but all share a common need: a partner with the technical depth, regulatory awareness, and manufacturing infrastructure to turn bold ideas into reality.

Unlike generalist CDMOs that treat phage as an afterthought, our entire platform was designed around phage CDMO partnerships. That means we understand the nuances of phage biology, from lytic phage amplification to filamentous phage display, from VLP assembly to regulatory guidance under FDA and EMA frameworks. When you work with Phage Biologics, you’re not starting from zero. You’re building on a foundation of expertise that already anticipates your challenges and speaks the language of your science. Our team doesn’t just manufacture — we collaborate, innovate, and scale alongside you, ensuring your program advances with precision and confidence.

This page outlines who we serve, how we serve them, and why Phage Biologics is the partner of choice for innovators worldwide. Whether your goal is to bring a therapeutic phage into the clinic, establish a display library, manufacture phage-derived vaccine scaffolds, or explore nanomaterials built from phage architectures, we are committed to supporting you at every stage. By aligning science, strategy, and execution, Phage Biologics enables the phage community to push boundaries and achieve breakthroughs that were once thought impossible.

Biotech Startups and Emerging Companies

Phage science is booming with early-stage innovation. Many of our partners are venture-backed biotech companies pushing bold ideas into development.

We support these companies with:

• Feasibility & Proof-of-Concept Work – Rapid phage amplification, small-batch purification, and infectivity testing.
• Platform Building – Establishing robust microbial expression systems for scalability.
• Regulatory Navigation – Guidance on FDA and EMA expectations for phage-based products.

Startups choose us because we act as an extension of their R&D team, not just a contract manufacturer. By providing flexible, right-sized support, we help early companies reach critical milestones without unnecessary overhead.

Mid-Sized Biopharma Companies

Mid-tier companies, often with multiple therapeutic programs, rely on us for scale-up and regulatory alignment.

We provide:

• Pilot to GMP Manufacturing – 10L bench-scale to 2000L+ fermentation for lytic phages.
• Analytical Development – qPCR identity testing, electron microscopy, and potency assays.
• Process Transfer – Seamless movement from academic protocols to reproducible, scalable systems.

Our role here is to de-risk clinical entry — ensuring your phage program doesn’t stall when scaling up or facing regulators.

Global Pharmaceutical Leaders

Large pharma companies turn to Phage Biologics for specialized expertise in areas outside their core capabilities.

We serve them by:

• Phage Display Platforms – Antibody, peptide, and ligand discovery at industrial scale.
• Vaccine Scaffolds – Phage-derived VLPs for infectious disease and oncology applications.
• Nanomaterial Programs – Engineered phages as carriers, wires, or topological scaffolds.

Global players value our ability to operate at GMP scale with regulatory readiness, while also acting as a source of innovation beyond traditional modalities.

Academic & Research Institutions

Academia has always been the cradle of phage innovation. We collaborate with universities, research hospitals, and government labs to translate science into application.

We provide:

• Custom Phage Libraries for discovery platforms.
• Pilot-Scale Manufacturing to bridge academic discoveries with translational work.
• Analytical Services that meet publication and grant requirements.

Our team is proud to serve as a bridge between academia and industry, helping brilliant ideas move beyond the lab bench into the clinic.

Government & Public Health Agencies

With antimicrobial resistance (AMR) recognized as a global crisis, public agencies are increasingly investing in phage-based solutions.

We partner with government groups to:

• Manufacture GMP-Grade Phages for compassionate use and clinical trials.
• Develop Stockpiles of phages targeting high-priority resistant pathogens.
• Support Biodefense Applications with phage-derived nanomaterials.

By working with Phage Biologics, agencies gain a specialist partner ready to meet both scientific and regulatory rigor.

Investors & Venture Funds

While not product developers themselves, investors and VCs rely on our expertise to evaluate opportunities and accelerate portfolio companies.

We provide:

• Technical Due Diligence on phage programs.
• Manufacturing Roadmaps to de-risk investments.
• Early Partnerships that give startups credibility with clinical and regulatory stakeholders.

When investors send their portfolio companies to Phage Biologics, they know they’re setting them up with the best phage CDMO in the world (and galaxy).

Therapeutic Focus Areas We Support

Antimicrobial Resistance (AMR)

Antimicrobial resistance is one of the greatest threats to global health, and phage therapy represents a uniquely powerful weapon against multidrug-resistant bacteria. Unlike small molecules or traditional antibiotics, phages bring precision targeting, adaptability, and the ability to evolve alongside bacterial hosts. At Phage Biologics, our platform is specifically designed to accelerate the development of phage therapeutics against resistant pathogens.

We support programs with:

• Lytic phages such as T4 and T7 targeting critical pathogens, including Klebsiella pneumoniae, E. coli, Pseudomonas aeruginosa, and Acinetobacter baumannii.
• Custom phage selection and amplification strategies to ensure high infectivity and reliable host range.
• GMP purification workflows with validated endotoxin clearance, ensuring safe therapeutic profiles and compliance with FDA and EMA expectations.
• Comprehensive QC analytics — infectivity assays, qPCR for identity and potency, electron microscopy for structural confirmation, and endotoxin testing aligned with regulatory thresholds.
• Regulatory support to align with emerging FDA/EMA guidelines for phage therapy submissions, including compassionate use programs and IND-enabling packages.

By focusing on AMR, we are not only advancing specific therapeutic programs but also contributing to the global effort to address one of the most urgent biomedical challenges of the century.

Oncology

Phage-derived scaffolds and virus-like particles (VLPs) are increasingly recognized as powerful tools in cancer immunotherapy. Phages provide stable, modular platforms that can be engineered to display tumor-associated antigens, stimulate immune responses, and serve as carriers for targeted therapies.

At Phage Biologics, we offer:

• Custom VLP design and capsid protein expression in microbial systems such as E. coli or yeast, allowing for scalable and reproducible manufacturing.
• Controlled assembly workflows to ensure uniform particle formation and optimized immunogenicity.
• Immunogenicity testing (in vitro and in vivo) to validate immune activation potential.
• Analytical services including electron microscopy (EM), dynamic light scattering (DLS), and binding assays to confirm particle stability and antigen display.
• GMP-scale production of vaccine scaffolds, complete with validated fill–finish operations to support both preclinical and clinical trials.

By combining technical rigor with creative engineering, we help oncology innovators turn phage-derived scaffolds into next-generation vaccines and immunotherapies.

Infectious Disease Vaccines

Beyond oncology, phages provide highly stable and immunogenic platforms for infectious disease vaccines. Their ability to display epitopes in a repetitive, multivalent manner makes them ideal candidates for stimulating protective immune responses.

Our team supports vaccine developers with:

• Scaffold functionalization, incorporating antigens or peptides of interest onto phage capsids or VLPs.
• Advanced structural analytics, including EM and DLS, to validate particle integrity, size distribution, and antigen display.
• Process development for stability, ensuring that phage-derived vaccines retain potency under storage and distribution conditions.
• GMP fill–finish operations, producing vials, prefilled syringes, or other delivery formats under aseptic conditions.
• Regulatory alignment, ensuring manufacturing and testing protocols meet global standards for vaccine submissions.

This combination of microbial scalability, robust immunogenicity, and regulatory foresight positions Phage Biologics as a trusted partner for infectious disease vaccine development.

Nanomedicine & Materials Science

Phages are more than therapies — they are programmable nanostructures with applications that extend into materials science, regenerative medicine, and advanced drug delivery. Their unique topologies, modularity, and natural ability to self-assemble make them ideal building blocks for next-generation biomaterials.

We work with innovators in nanomedicine to:

• Engineer phages as nanowires for biosensing, electronics, and structural applications.
• Develop phage-based scaffolds for drug delivery systems, regenerative tissue engineering, and targeted biomaterial design.
• Apply protein engineering to capsid and coat proteins, creating custom architectures and novel topologies for specific use cases.
• Scale production under microbial fermentation systems, ensuring reproducibility, purity, and cost-effectiveness.

By enabling phages to function as biological machines, we help our partners push beyond traditional healthcare into the realm of biofabrication and programmable nanotechnology.

Why Clients Choose Phage Biologics

• Phage-First Identity – Unlike generalist CDMOs, phages are not a side offering for us; they are our DNA. Every piece of infrastructure, every assay, and every workflow has been designed around the unique requirements of phage-based biologics.
• End-to-End Platform – From early discovery and feasibility studies to IND-enabling work and GMP commercial production, we offer the full spectrum of services under one roof. This seamless integration reduces tech transfer risks, shortens timelines, and improves cost efficiency.
• Regulatory Alignment – Our team has deep expertise in FDA and EMA phage therapy pathways, including emerging frameworks for phage VLP vaccines, phage display libraries, and nanomaterial applications. We ensure your program is aligned with the latest regulatory expectations.
• Innovation Partnership – We don’t just manufacture — we collaborate. Our scientists and engineers bring decades of experience in microbial systems, protein engineering, and analytical development, working side by side with you to refine designs, optimize processes, and de-risk scale-up.
• Scalable Microbial Systems – With microbial expression systems as our backbone, we can scale from benchtop fermentations to GMP facilities producing clinical and commercial batches. This microbial-first philosophy ensures rigor, reproducibility, and scalability across all projects.

At Phage Biologics, clients don’t just get a CDMO — they gain a partner committed to advancing their science, accelerating their timelines, and shaping the future of phage-based innovation.

Global Reach & Future Readiness

We proudly serve clients across North America, Europe, and Asia. As phage science grows, we continue to expand capacity, scale, and partnerships to ensure phage biologics reach patients and markets worldwide.

Closing Statement

At Phage Biologics, we don’t just serve clients — we cultivate lasting partnerships that move the entire phage field forward. Our mission extends beyond manufacturing: we work shoulder to shoulder with innovators to shape strategies, solve technical challenges, and accelerate breakthroughs. Each collaboration becomes a shared journey, one where our expertise and infrastructure amplify your vision.

Whether you are a startup chasing your first milestone, a pharma company scaling global programs, or an academic pioneer pushing the boundaries of discovery, our role is to provide not only the technical capabilities but also the strategic guidance needed to succeed. For early-stage companies, that means helping transform raw ideas into viable therapeutic candidates with scalable processes. For established pharma partners, it means delivering the GMP rigor and regulatory alignment necessary to move confidently into the clinic and beyond. For academics, it means bridging discovery with translational reality, ensuring your science has a clear pathway to impact.

Together, we aim to unlock the full potential of phages — as therapies against drug-resistant bacteria, as scaffolds for vaccines and immunotherapies, and as programmable nanostructures that can redefine biotechnology. Every project we take on contributes not just to an individual program’s success, but to the collective momentum of a field on the rise.

Want to learn more about our Services?

Here is link to our Service page–> Phage Biologics CDMO Services page

Contact our team at info@phagebiologics.com